Core Viewpoint - The launch of China's first ophthalmic air medical project based on domestically produced large aircraft aims to transform C919 and other aircraft into specialized flying hospitals equipped with domestic devices and intelligent remote systems, achieving the goal of "aircraft arrival, light arrival" [1][3]. Group 1: Background and Motivation - The case of Chen Ziyong, a patient from a remote area suffering from diabetic retinopathy, highlights the urgent need for advanced eye care services, as many patients seek treatment at top facilities like Zhongshan Ophthalmic Center as a last resort [2][7]. - Zhongshan Ophthalmic Center is ranked first in the national ophthalmology specialty reputation rankings, indicating its leading position in the field [2][3]. Group 2: Medical Resource Distribution - There are over 60,000 ophthalmologists in China, with a limited number capable of performing intricate eye surgeries, leading to a significant gap in eye care services, especially in remote areas [6][11]. - The prevalence of cataracts is notably high, with an 80% incidence rate among individuals over 60 years old, exacerbating the need for accessible eye care [7]. Group 3: Technological Innovations - The introduction of high-precision ophthalmic surgical robots offers a viable solution to the challenges of surgical difficulty and precision, enabling operations with micron-level accuracy and filtering out hand tremors from surgeons [12][13]. - The successful development of these robots can enhance the safety and success rates of surgeries, while also expanding the reach of quality medical services to underserved areas through remote operation capabilities [13]. Group 4: Future Aspirations - The establishment of the "Ophthalmic Flying Hospital" represents a significant step towards creating a self-sufficient and advanced eye care system in China, with collaborations among various organizations to promote this initiative [17]. - The vision of a "magic mirror" that can assess eye health and provide real-time feedback to patients reflects the innovative approach of Zhongshan Ophthalmic Center in integrating technology into eye care [17][18].

经济观察报 记者 张锐 58岁的陈自勇来自云南省红河哈尼族彝族自治州大庄乡，他到中山大学中山眼科中心（下称"中山眼科中心"）求医时，双眼已经因糖尿病眼底病变几乎失 明。 "这是我们的最后一站。"9月18日，陈自勇的妻子对经济观察报记者说，"找回一些光感都可以，那和看不见（完全失明）不一样，那一点光是他觉得自己没 有被生活打败的信心和希望。" 陈自勇这样的求医群体，也是中山眼科中心启动眼科"飞行医院"建设的重要动力之一。 9月10日，经济观察报记者从广东省新闻办举行的"广东卫生健康新质生产力"新闻发布会上获悉，我国首个基于国产大飞机的眼科航空医疗项目正式启动， 未来C919等国产大飞机将被改装为专业眼科飞行医院，搭载国产设备与智能远程系统，实现"飞机到、光明到"。 当天，中山眼科中心主任林浩添在接受媒体访问时表示，今年底，计划在新疆塔县实现"中国眼科飞行医院"首飞。 医疗资源的稀缺与错位 "全国眼科医生只有6万多名，能做精细眼科手术的医生就更少了。"9月10日，中山眼科中心博士徐安迪向经济观察报记者表示。 根据中山眼科中心的统计数据，白内障是全国第一大致盲眼病，60岁以上人群的白内障患病率高达80%。而同时，大 ...

Core Insights - The article discusses the advancements and upcoming events in the field of ophthalmic surgery robotics, particularly focusing on the ORYOM™ platform developed by ForSight Robotics, which aims to address the challenges in cataract surgery through automation and precision [2][18]. Group 1: Industry Context - There are over 600 million cataract patients globally, with only about 30 million surgeries performed annually, indicating a significant gap in treatment availability [3]. - The supply of ophthalmologists is declining, with an expected 12% decrease in the number of doctors by 2035, while demand is projected to increase by 24% [3]. Group 2: Technological Advancements - The ORYOM™ platform is the first AI-based ophthalmic surgical robot, designed specifically for eye surgery, featuring micro-robots, AI algorithms, and intraoperative imaging systems [7][10]. - The platform has demonstrated high precision in animal models, completing cataract surgeries with an average time of 277 seconds and low complication rates [7][8]. Group 3: Clinical Development - ForSight Robotics has received ISO 13485 certification and plans to initiate its first human clinical trial in 2025, focusing on the safety and preliminary effectiveness of the ORYOM™ platform [16]. - The trial is expected to include 10-30 patients and will assess key metrics such as capsular integrity and intraocular lens centration [16]. Group 4: Future Directions - The company aims to standardize surgical procedures by programming optimal surgical action sequences, potentially reducing reliance on surgeon skill and enhancing safety [17]. - The ORYOM™ platform is uniquely designed for ophthalmic procedures, differentiating itself from existing surgical robots in other fields, and may become the first to enter human trials in ophthalmic surgery [18].

Core Viewpoint - The article highlights the advancements and funding achievements of Dishi Medical, particularly focusing on its eye surgery robot "Dishi Weifeng," which aims to enhance precision in ophthalmic surgeries and address the shortage of skilled ophthalmologists in China [1][3][19]. Company Overview - Dishi Medical was established in July 2021, specializing in the development of ultra-microsurgery robots, particularly for ophthalmic procedures, achieving a motion precision of up to 3 micrometers [19]. - The company has completed multiple rounds of financing in 2023, including a nearly 100 million yuan A-round led by Panlin Capital [1][2][3]. Product Development - The "Dishi Weifeng" eye surgery robot is the first in China to enter multi-center clinical trials, with a focus on improving the success rate of retinal injections from 85.5% to 100% when assisted by the robot [3][4]. - The robot operates with a master-slave control system, allowing for precise operations in confined spaces, addressing the challenges posed by human physiological tremors [5][4]. Clinical Trials and Applications - The robot has successfully completed its first clinical applications in Asia, assisting in surgeries for retinal hemorrhage, demonstrating its potential in treating age-related macular degeneration [12][11]. - The first multi-center clinical trial for the "Dishi Weifeng" robot commenced in June 2024, with successful patient enrollments at leading hospitals [9]. Market Potential - The article discusses the growing interest and development of ophthalmic surgical robots globally, with various international players already demonstrating their capabilities [16]. - In China, despite a late start, the field is rapidly evolving, with several innovative companies and research teams entering the market, indicating a promising future for robotic-assisted eye surgeries [16][17][18]. Future Prospects - Dishi Medical plans to expand its technology beyond ophthalmology into other microsurgical fields, aiming to create a platform technology applicable across various medical specialties [8][19]. - The advancements in robotic technology are expected to significantly enhance surgical precision and patient outcomes, paving the way for broader adoption in the medical field [18].

Core Viewpoint - The increasing prevalence of retinal diseases due to global aging presents significant challenges in ophthalmic healthcare, necessitating advanced surgical solutions like ophthalmic surgical robots to meet the precision demands of treatments [2][6][28]. Group 1: Industry Context - The rise in retinal diseases such as macular degeneration and diabetic retinopathy is linked to an aging population, leading to a higher demand for precise and minimally invasive surgical interventions [2]. - Traditional manual surgical methods are limited by human factors such as hand tremors, making it difficult to achieve the required precision for procedures involving small blood vessels [6][10]. Group 2: Technological Advancements - Ophthalmic surgical robots developed by companies like Xianwei Medical are designed to overcome the limitations of manual surgery, offering high precision and stability essential for complex procedures [6][12]. - Key technological features of these robots include dual-arm control, micron-level positioning accuracy, and advanced algorithms for motion scaling and dynamic compensation [11][12]. Group 3: Product Development - Xianwei Medical has introduced the first domestic eyelid gland thermal pulsation treatment device, addressing the rising incidence of dry eye syndrome caused by meibomian gland dysfunction [23][25]. - The device utilizes direct heating technology to effectively treat the underlying causes of dry eye, offering a more efficient and safer alternative to existing treatments [25][27]. Group 4: Clinical Validation and Market Strategy - The thermal pulsation device has undergone clinical validation, demonstrating significant improvements in meibomian gland secretion and prolonged relief from dry eye symptoms [27]. - Xianwei Medical's strategy includes diversifying its product offerings to stabilize cash flow and mitigate market uncertainties, with the thermal pulsation device serving as a quick-to-market solution [27][28]. Group 5: Future Outlook - The company aims to reshape the treatment landscape for retinal diseases and dry eye syndrome through continuous innovation and a focus on clinical needs, leveraging intelligent technology for enhanced patient outcomes [28][29].